Invention Grant
- Patent Title: 6-membered heteroaromatic substituted cyanoindoline derivatives as NIK inhibitors
-
Application No.: US16071298Application Date: 2017-01-20
-
Publication No.: US11001569B2Publication Date: 2021-05-11
- Inventor: Ian Stansfield , Olivier Alexis Georges Querolle , Gerhard Max Gross , Edgar Jacoby , Lieven Meerpoel , Janusz Jozef Kulagowski , Calum Macleod , Samuel Edward Mann , Simon Richard Green , George Hynd
- Applicant: Janssen Pharmaceutica NV
- Applicant Address: BE Beerse
- Assignee: Janssen Pharmaceutica NV
- Current Assignee: Janssen Pharmaceutica NV
- Current Assignee Address: BE Beerse
- Priority: EP16152414 20160122,EP16152415 20160122,EP16159658 20160310,EP16159659 20160310
- International Application: PCT/EP2017/051160 WO 20170120
- International Announcement: WO2017/125534 WO 20170727
- Main IPC: C07D401/14
- IPC: C07D401/14 ; C07D403/14 ; C07D405/14 ; C07D413/14 ; A61P35/00
Abstract:
The present invention relates to pharmaceutical agents of formula (I), useful for therapy and/or prophylaxis in a mammal, and in particular to inhibitors of NF-κB-inducing kinase (NIK—also known as MAP3K14) useful for treating diseases such as cancer, inflammatory disorders, metabolic disorders and autoimmune disorders. The invention is also directed to pharmaceutical compositions comprising such compounds, and to the use of such compounds or pharmaceutical compositions for the prevention or treatment of diseases such as a cancer, inflammatory disorders, metabolic disorders including obesity and diabetes, and autoimmune disorders.
Information query
